Antares/Otter Patent-Cliff Exposure & CMS Drug Spending Portfolio

Antares/Otter (US): 1 reconciled FDA prescription therapies, $10.8M 2024 CMS Part D & Medicaid spend, and 14 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$10.8M
2024 Medicare Part D Spend$7.5M
2024 Medicaid Spend$3.2M
California HCAI SB 17 Filings14 WAC filings (max 18.8% 2-yr change)